Rapport Therapeutics, Inc. (RAPP)
| Market Cap | 791.02M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -51.31M |
| Shares Out | 34.32M |
| EPS (ttm) | -1.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 49,201 |
| Open | 22.24 |
| Previous Close | 22.21 |
| Day's Range | 22.01 - 23.67 |
| 52-Week Range | 18.00 - 28.08 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 35.00 (+51.84%) |
| Earnings Date | Aug 12, 2024 |
About RAPP
Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TAR... [Read more]
Analyst Forecast
According to 3 analysts, the average rating for RAPP stock is "Strong Buy." The 12-month stock price forecast is $35.0, which is an increase of 51.84% from the latest price.
News
Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement
BOSTON and SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small...
J&J-backed Rapport Therapeutics valued at $636.8 mln after shares rise 6% in debut
Shares of Rapport Therapeutics , backed by Johnson & Johnson's venture capital arm, rose nearly 6% in their market debut on Friday, valuing the early stage therapy developer at $636.8 million.
J&J-backed Rapport Therapeutics raises $136 mln in US IPO
Rapport Therapeutics said on Thursday that it has raised $136 million in its initial public offering in the United States at a valuation of about $601.4 million.
Rapport Therapeutics Announces Pricing of Initial Public Offering
BOSTON and SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small...
J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO
Rapport Therapeutics is targeting a valuation of about $637 million in its initial public offering in the United States, as the biopharmaceutical company joins a slew of firms looking to list their sh...
J&J-backed startup Rapport files for US IPO
Biopharmaceutical company Rapport Therapeutics, backed by the venture capital arm of Johnson & Johnson , filed for an initial public offering in the United States on Friday.
CNS disorder biotech Rapport Therapeutics files for a $100 million IPO
Rapport Therapeutics, a Phase 2-ready biotech developing small molecule therapies for CNS disorders, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Rapport Therapeutics IPO Registration Document (S-1)
Rapport Therapeutics has filed to go public with an IPO on the NASDAQ.